Serkan Kuyumcu

List of Publications by Year
in descending order

49 papers	963 citations	471509 17 h-index	477307 29 g-index
49 all docs	49 docs citations	49 times ranked	1332 citing authors

#	Article	IF	Citations
1	68Ga-PSMA Uptake Patterns of Clear Cell Renal Carcinoma Across Different Histopathological Subtypes. Clinical Nuclear Medicine, 2022, 47, e45-e46.	1.3	8
2	Fibroblast Activation Proteinâ€“Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT. Clinical Nuclear Medicine, 2022, 47, e54-e55.	1.3	18
3	Intratumoral Heterogeneity in a Patient With Metastatic Thymic Carcinoma on 18F-FDG, 68Ga-DOTATATE, and 68Ga-FAPI04 PET/CT. Clinical Nuclear Medicine, 2022, 47, e79-e80.	1.3	2
4	Comparison of 2D planar and 3D volumetric methods for estimation of split renal function by 99mTc-DMSA scintigraphy. Physica Medica, 2022, 95, 83-88.	0.7	2
5	Outcome of 177Lu-PSMA Radionuclide Treatment in Advanced Prostate Cancer and Its Association With Clinical Parameters. Clinical Nuclear Medicine, 2022, 47, e521-e528.	1.3	7
6	YÃœKSEK RÄ°SKLÄ° PROSTAT KANSERÄ°NDE 68GA-PSMA PET/BTâ€™NÄ°N TEDAVÄ° YÃ–NETÄ°MÄ°NE ETKÄ°SÄ°. Ä°stanbul TÄ±p FakÃ Dergisi, 2021, 84, .	0.1	1
7	Somatostatin receptor-positive breast lesions on 68Ga-DOTATATE PET/CT. Annals of Nuclear Medicine, 2021, 35, 270-277.	2.2	2
8	Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer?. Annals of Nuclear Medicine, 2021, 35, 680-690.	2.2	11
9	Safety of Fibroblast Activation Proteinâ€“Targeted Radionuclide Therapy by a Low-Dose Dosimetric Approach Using 177Lu-FAPI04. Clinical Nuclear Medicine, 2021, 46, 641-646.	1.3	52
10	177Lu-PSMA Therapy for Metastatic Testicular Mixed Germ Cell Tumor. Clinical Nuclear Medicine, 2021, 46, 415-418.	1.3	3
11	Demonstration of in vivo estrogen receptor status with 16Î±- [18F]fluoro-17ÃŸ-oestradiol (FES) PET/CT in a rare case of benign metastasizing leiomyoma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4101-4102.	6.4	3
12	Liver metastases from medullary thyroid carcinoma detected on 68Ga-FAPI-04 PET/CT. Endocrine, 2021, 74, 727-728.	2.3	8
13	Prognostic significance of 68Ga-Pentixafor PET/CT in multiple myeloma recurrence: a comparison to 18F-FDG PET/CT and laboratory results. Annals of Nuclear Medicine, 2021, 35, 1147-1156.	2.2	18
14	CXCR4 Expression Demonstrated by 68Ga-Pentixafor PET/CT Imaging in a Case of Systemic Mastocytosis Mimicking Lymphoma. Clinical Nuclear Medicine, 2021, Publish Ahead of Print, e563-e564.	1.3	1
15	225Ac-Prostate-Specific Membrane Antigen Therapy for Castration-Resistant Prostate Cancer. Clinical Nuclear Medicine, 2021, 46, 943-951.	1.3	11
16	Prognostic value of FDG PET-CT in suspected recurrence of colorectal carcinoma: survival outcomes of a 10-year follow-up. Annals of Nuclear Medicine, 2021, , 1.	2.2	1
17	Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management. Frontiers in Oncology, 2021, 11, 758958.	2.8	25
18	Does bone scintigraphy still have a role in the era of 68ÂGa-PSMA PET/CT in prostate cancer?. Annals of Nuclear Medicine, 2020, 34, 476-485.	2.2	15

#	Article	IF	Citations
19	Clinical Impact of Lower-Limb Imaging in ⁶⁸Ga-PSMA PET/CT for Patients with Prostate Cancer. Journal of Nuclear Medicine Technology, 2019, 47, 233-237.	0.8	6
20	Radionuclide Therapy With 177Lu-PSMA in a Case of Metastatic Adenoid Cystic Carcinoma of the Parotid. Clinical Nuclear Medicine, 2019, 44, 764-766.	1.3	13
21	Evidence of Prostate-Specific Membrane Antigen Expression in Hepatocellular Carcinoma Using 68Ga-PSMA PET/CT. Clinical Nuclear Medicine, 2019, 44, 702-706.	1.3	34
22	POST-THERAPY IMAGING AFTER RADIOACTIVE IODINE THERAPY FOR DIFFERENTIATED THYROID CANCER: THE CONTRIBUTION OF SPECT-CT IMAGING TO PLANAR IMAGING. European Oral Research, 2019, 81, 106-114.	0.9	0
23	MALIGN PLEVRAL MEZOTELYOMA AYIRICI TANISI VE PROGNOZUNDA 18F-FDG PET/BTâ€™NÄ°N ROLÃœ. Ä°stanbul TÄ±p FakÃ¼ltesi Dergisi, 2019, 82, .	0.1	0
24	68Ga-DOTATATE PETâ€“CT imaging in carotid body paragangliomas. Annals of Nuclear Medicine, 2018, 32, 297-301.	2.2	9
25	Imaging of Chemokine Receptor CXCR4 in Mycosis Fungoides Using 68Ga-Pentixafor PET/CT. Clinical Nuclear Medicine, 2018, 43, 606-608.	1.3	10
26	Neuroendocrine Tumor Diagnosis and Management: ⁶⁸Ga-DOTATATE PET/CT. American Journal of Roentgenology, 2018, 211, 267-277.	2.2	133
27	Clinical Utility of Tc-99m MIBI SPECT/CT for Preoperative Localization of Parathyroid Lesions. Indian Journal of Surgery, 2017, 79, 312-318.	0.3	5
28	Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer. Annals of Nuclear Medicine, 2017, 31, 709-717.	2.2	37
29	Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of 18FDG-PET/CT according to Î”SUVmax, Deauville 5-point scale and IHP criteria. Annals of Nuclear Medicine, 2017, 31, 660-668.	2.2	21
30	Correlation of 18F-FDG PET/CT with pathological features and survival in primary breast cancer. Nuclear Medicine Communications, 2017, 38, 694-700.	1.1	14
31	Do 18F-FDG PET/CT findings have a relationship with histopathological and immunohistochemical factors of breast cancer in men?. Nuclear Medicine Communications, 2016, 37, 1273-1281.	1.1	6
32	An Incidental Solitary Plasmacytoma of Bone Mimicking Neuroendocrine Tumor Metastasis on 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography. Molecular Imaging and Radionuclide Therapy, 2016, 25, 147-149.	0.7	8
33	Favorable Survival Time Provided with Radioembolization in Hepatocellular Carcinoma Patients with and Without Portal Vein Thrombosis. Cancer Biotherapy and Radiopharmaceuticals, 2015, 30, 132-138.	1.0	19
34	Comparison of 68Ga-DOTATATE PET-CT, 18F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma. Nuclear Medicine Communications, 2015, 36, 242-250.	1.1	42
35	Does Metastatic Lymph Node SUVmax Predict Survival in Patients with Esophageal Cancer?. Molecular Imaging and Radionuclide Therapy, 2015, 24, 120-127.	0.7	3
36	Candida esophagitis mimicking esophageal malignancy on 18FDG PET/CT. Turkish Journal of Gastroenterology, 2015, 26, 63-64.	1.1	6

#	Article	IF	Citations
37	Can Complementary ⁶⁸Ga-DOTATATE and ¹⁸F-FDG PET/CT Establish the Missing Link Between Histopathology and Therapeutic Approach in Gastroenteropancreatic Neuroendocrine Tumors?. Journal of Nuclear Medicine, 2014, 55, 1811-1817.	5.0	82
38	Impact of Nonosseous Findings on 18F-NaF PET/CT in a Patient with Ductal Breast Carcinoma. Nuclear Medicine and Molecular Imaging, 2014, 48, 72-74.	1.0	6
39	Survival analysis of Yâ€90 radiosynovectomy in the treatment of haemophilic synovitis of the knee: a 10â€year retrospective review. Haemophilia, 2014, 20, e45-50.	2.1	28
40	Physiological and tumoral uptake of 68Ga-DOTATATE: standardized uptake values and challenges in interpretation. Annals of Nuclear Medicine, 2013, 27, 538-545.	2.2	78
41	Microscopic polyangiitis on 18F-FDG PET/CT of a patient with fever of unknown origin presenting as isolated diffuse renal hypermetabolism. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1295-1296.	6.4	4
42	The Value of Somatostatin Receptor Imaging with In-111 Octreotide and/or Ga-68 DOTATATE in Localizing Ectopic ACTH Producing Tumors. Molecular Imaging and Radionuclide Therapy, 2013, 22, 49-55.	0.7	34
43	Hepatic Adenomatosis May Mimic Metastatic Lesions of Liver With 18F-FDG PET/CT. Clinical Nuclear Medicine, 2012, 37, 697-698.	1.3	20
44	The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels. Annals of Nuclear Medicine, 2012, 26, 551-558.	2.2	53
45	Somatostatin receptor scintigraphy with 111In-octreotide in pulmonary carcinoid tumours correlated with pathological and 18FDG PET/CT findings. Annals of Nuclear Medicine, 2012, 26, 689-697.	2.2	21
46	Increased FDG uptake in breast cancer is associated with prognostic factors. Annals of Nuclear Medicine, 2012, 26, 345-350.	2.2	57
47	Role of red blood cell scintigraphy for determining the localization of gastrointestinal bleeding. Ulusal Travma Ve Acil Cerrahi Dergisi, 2012, 18, 225-230.	0.3	2
48	Diagnostic spectrum of congenital hypothyroidism in Turkish children. Pediatrics International, 2009, 51, 464-468.	0.5	23
49	[68Ga]-Pentixafor PET/CT imaging of lymphoproliferative malignancies. Clinical and Translational Imaging, 0, , 1.	2.1	1